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Abstract: CHMP2B mutations are a rare cause of autosomal dominant frontotemporal dementia (FTD). The best studied 
example is frontotemporal dementia linked to chromosome 3 (FTD-3) which occurs in a large Danish family, with a fur-
ther CHMP2B mutation identified in an unrelated Belgian familial FTD patient. These mutations lead to C-terminal trun-
cations of the CHMP2B protein and we will review recent advances in our understanding of the molecular effects of these 
mutant truncated proteins on vesicular fusion events within the endosome-lysosome and autophagy degradation pathways. 
We will also review the clinical features of FTD caused by CHMP2B truncation mutations as well as new brain imaging 
and neuropathological findings. Finally, we collate the current data on CHMP2B missense mutations, which have been re-
ported in FTD and motor neuron disease. 
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INTRODUCTION 
  Frontotemporal lobar degeneration (FTLD) comprises a 
heterogeneous group of disorders which are all characterised 
by gross atrophy primarily of the frontal and/or temporal 
lobes. FTLD generally presents with either personality 
change, termed behavioural variant frontotemporal dementia 
(bvFTD) (or simply FTD) or distinct language impairments 
termed language variant FTD (lv-FTD), including semantic 
dementia (SD) and progressive non-fluent aphasia (PNFA) 
[1, 2]. FTLD can also be associated with parkinsonism, or 
with motor neuron disease, which is termed FTD-MND [3]. 
FTLD also has clinical and neuropathological overlap with 
the atypical parkinsonian movement disorders corticobasal 
degeneration (CBD) and progressive supranuclear palsy 
(PSP) [4-7]. 
  The neuropathology of FTLD syndromes is also hetero-
geneous. The two major pathologies are FTLD-tau and 
FTLD-TDP, which are characterised by tau or TDP-43 posi-
tive inclusions respectively [4, 8]. FUS-positive inclusions 
have recently been described in a subset of FTLD cases [9, 
10], and two rare neuropathological subtypes remain: those 
with ubiquitin-positive inclusions that are negative for tau, 
TDP-43 and FUS, termed FTLD-UPS [11] (which are pri-
marily,  CHMP2B mutation cases), and those with no dis-
cernable inclusions, termed FTLD-ni [11]. 
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  The major genetic causes of FTLD are mutations in GRN 
[12, 13], which encodes progranulin and MAPT [14] which 
encodes tau, leading to FTLD-TDP and FTLD-tau respec-
tively. Mutations in TARDBP (which encodes TDP-43) [15, 
16], VCP [17], FUS [18] and CHMP2B [19, 20] are much 
rarer genetic causes of FTLD. This review will focus on re-
cent advances in the brain imaging, neuropathology, cell 
biology and genetics of FTLD caused by CHMP2B muta-
tions. 
C-TERMINAL TRUNCATION MUTATIONS IN FA-
MILIAL FTD 
  The first mutation in CHMP2B was identified in fronto-
temporal dementia linked to chromosome 3 (FTD-3) [20], an 
autosomal dominant FTD which occurs in one large kindred 
from Denmark [20, 21]. The mutation occurs in the splice 
acceptor site for the 6
th and final CHMP2B exon, leading to 
the formation of two novel transcripts termed CHMP2B
Intron5 
and CHMP2B
Delta10. Both transcripts are present in the brains 
of FTD-3 patients: CHMP2B
Intron5
 at ~35% and CHMP2B
Delta10 
at ~10% the level of the wildytpe CHMP2B transcript [22]. 
The resulting proteins both lose the final 36 amino acids, 
which are encoded by exon 6, replacing them with either a 
single valine residue (CHMP2B
Intron5) or a 29 amino acid 
nonsense sequence (CHMP2B
Delta10) Fig. (1). A second 
CHMP2B mutation was subsequently identified in an auto-
somal dominant Belgian FTLD pedigree [19]. This mutation 
changes a glutamine residue at position 165 of the CHMP2B 
protein sequence to a stop codon and is therefore termed 
CHMP2B
Q165X. This leads to a protein which lacks the final Frontotemporal Dementia Caused by CHMP2B Mutations  Current Alzheimer Research, 2011, Vol. 8, No. 3    247 
49 amino acids Fig. (1). Importantly, it therefore appears that 
the mutations have a common mechanism - the deletion of 
the C-terminus of the protein [23]. 
CLINICAL FINDINGS 
  The most comprehensive clinical picture of FTLD caused 
by  CHMP2B mutation comes from the description of 22 
FTD-3 patients [24] (of the 33 FTD-3 cases identified to 
date). Early personality change is the most common feature 
which can include less concern for others, an unkempt ap-
pearance, disinhibition, inappropriate emotional responses 
and restlessness which later can be accompanied by aggres-
sion. Apathy can also occur as the disease progresses. Hy-
perorality is also common, encompassing mouthing of non-
food objects, over-eating of sweet foods and chain smoking. 
Early dyscalculia was observed in 8 of the 22 patients and 
was the presenting symptom in one case. Sterotyped behav-
ioural routines were observed in 11 of the 22 patients. For 
example, one patient continuously walked round the outside 
of her house and another repeatedly turned objects upside 
down to inspect their bases. Apraxia is also common with 
patients unable to copy gestures. A progressive aphasia de-
velops during the course of the disease, although normally 
not with features of PNFA or SD. It is characterised by re-
duced spontaneous speech with relative preservation of read-
ing and repetition, most consistent with a dynamic aphasia. 
An overt motor syndrome develops late in the disease course 
which can include parkinsonian features, dystonia, pyramidal 
signs and myoclonus, ultimately leaving the patients bedrid-
den. None of the patients have had any clinical signs of ei-
ther upper or lower motor neuron impairment, and no neuro-
physiological EMG studies have been done so far in the 
Danish FTD-3 patients. A new branch of the FTD-3 family 
was recently identified and clinical descriptions of a further 
two cases were similar to those previously reported [21]. The 
average age of onset for FTD-3 is 58 years of age and the 
mean duration is 10 years. Ongoing neuropsychological 
studies indicate that some of the patients can have impaired 
memory function in the earlier phases of the disease, but this 
is not a prominent feature and most often not a subjective 
complaint by the patients. 
  The clinical picture of the Belgian CHMP2B mutation 
patient has some similarities to the FTD-3 cases including 
loss of decorum, mild disinhibtion and severe dyscalculia 
early in the disease course [19]. The presenting symptom 
was dysgraphia [19] which has not been reported in any 
FTD-3 case. 
BRAIN IMAGING IN FTD-3 
Structural Imaging 
  In patients with clinical FTD-3 disease computerised 
tomography (CT) scans have been performed in 9 cases [21, 
24] and MRI has been reported in one case [24], with scans 
performed on 3 further patients (our unpublished data). At 
diagnosis the scans shows a generalised central and cortical 
atrophy. There is no anterior or lateral preponderance. The 
posterior central atrophy might be more pronounced al-
though the number of patients studied has been limited [24]. 
MRI on one patient has shown some non-specific white mat-
ter hyper intensities on T2 and Flair Imaging, which were 
considered most likely not directly related to FTD-3. A gen-
eralised atrophy was observed which was most marked in the 
frontal parietal and occipital lobes [24]. 
  MRI in presymptomatic CHMP2B mutation carriers 
compared to first degree relatives without the mutation indi-
cated that a global [25] as well as focal cortical atrophy [26] 
can occur before onset of symptoms. 
  Two CT scans have been performed on the Belgian 
CHMP2B mutation positive case [19]. The first scan was 
performed 2 years after symptom onset and showed mild 
frontal atrophy. A second CT scan 6 years into the disease 
course showed a generalised atrophy. 
Functional CBF Imaging in FTD-3 
  Measurements of regional cerebral blood flow (rCBF) 
with H2
15O positron emission tomography (PET) has been 
performed in 3 FTD-3 patients with MMSE ranging from 0-
24 points [21, 24]. The rCBF was normal in the primary vis-
ual cortex, thalami, basal ganglia, cerebellum, and in the 
more mild patients also in a small area of the right lateral 
frontal cortex. The rCBF of all other cortical regions was 
severely impaired with the most prominent flow deficits in 
the parietal, anterior-frontal, and lateral temporal cortices. 
Representative MRI and PET scans are shown in Fig. (2). 
NEUROPATHOLOGY 
  FTD-3 brains show a global cortical atrophy, which is 
most marked in the frontal cortex but also prominent in the 
temporal cortex; the parietal lobe can also be affected but the 
cerebellum is spared [24, 27]. There is no obvious atrophy of 
the hippocampus, amygdala, basal ganglia or substantia nigra 
[24, 27]. Cortical neuronal loss is accompanied by gliosis 
and microvacuolisation [24, 27]. Ubiquitin- and p62-positive 
neuronal cytoplasmic inclusions are observed in FTD-3 
brains in the dentate granule cell layer of the hippocampus 
and to a lesser extent in the frontal cortex [27]. These inclu-
sions are negative for both TDP-43 [27] and FUS [28], clas-
sifying FTD-3 as FTLD-UPS. We recently reported that two 
familial FTLD-UPS cases were negative for CHMP2B muta-
tion [29], suggesting that although FTLD-UPS is a rare 
FTLD pathology it has more than one genetic cause. 
  The neuropathology of FTD-3 has been further refined 
by the discovery of enlarged vacuoles in cortical neurons 
[22]. The vacuoles were present in the frontal, temporal, pa-
rietal and occipital cortices, but not in the cerebellar cortex, a 
pattern generally reflecting the atrophy observed by neuropa-
thology and brain imaging. The vacuoles were positive for a 
marker to the late endosome, suggesting they could be aber-
rant enlarged late endosomes. Enlarged endosomes have not 
been described in other FTLD cases to date, although en-
larged early and late endosomes have been observed in corti-
cal neurons in Down’s syndrome and Alzheimer’s disease 
brains [30-32]. 
  FTD-3 brains have no abnormal a,  -synuclein, prion 
protein or neurofilament staining [27]. Some tau pathology 
has been observed, but at insufficient levels for a diagnosis 
of FTLD-tau. Tau positive inclusions were identified in the 
frontal cortex of three FTD-3 brains, but at levels that could 
be explained by normal aging [33]. Tau staining in further 248    Current Alzheimer Research, 2011, Vol. 8, No. 3  Isaacs et al. 
brain regions of the same cases, as well as one additional 
case, revealed neurofibrillary tangles, in the absence of amy-
loid deposits, in the hippocampus, entorhinal cortex and 
transentorhinal cortex consistent with Braak stage IV [27]. 
This distribution of neurofibrilliary tangles in the absence of 
amyloid pathology is typical of tangle predominant dementia 
[34, 35], but such cases are clinically distinct from FTD-3, 
presenting with an Alzheimer’s disease-like dementia with 
very late onset (80-90 years of age) [34, 35]. 
FUNCTIONAL STUDIES 
  CHMP2B is part of the multi-protein ESCRT-III com-
plex (endosomal sorting complex required for transport-III). 
ESCRT-III has a role in two protein degradation pathways 
that converge on the lysosome: the endosome-lysosome 
pathway and autophagy. The CHMP2B C-terminal trunca-
tion mutants can impair both of these pathways and each will 
be discussed. 
Endosome-Lysosome Pathway 
  The endosome-lysosome pathway is responsible for the 
degradation of endocytosed proteins such as transmembrane 
proteins and cell surface receptors. The proteins are endocy-
tosed into early endosomes which mature into late en-
dosomes and then fuse with lysosomes, allowing protein 
degradation to occur. Over-expression of CHMP2B
Intron5, 
CHMP2B
Delta10 or CHMP2B
Q165X in human neuroblastoma 
cells leads to the formation of enlarged late endosomes [19], 
suggesting an impairment of this pathway. The relevance of 
this cell culture data was confirmed by the observation of 
aberrant enlarged late endosomes in fibroblasts from both 
FTD-3 patients and the Belgian CHMP2B mutation patient, 
as well as the identification of enlarged endosomes in corti-
cal neurons in FTD-3 patient brain [22]. Further cell culture 
data indicates that this defect is due to the C-terminal 
CHMP2B mutants impairing the fusion of endosomes with 
lysosomes [22]. The late endosomes in CHMP2B mutant 
cells were impaired in their ability to recruit Rab7 [22], a key 
member of the endosome-lysosome fusion machinery [36]. 
RAB7 mutations have been identified in the rare motor and 
sensory neuropathy Charcot-Marie-Tooth type 2B [37, 38], 
suggesting altering Rab7 function can lead to neurodegenera-
tive disease. 
  How impairment of endosome-lysosome fusion leads to 
disease is still not clear. The ESCRT complex mediates the 
lysosomal degradation of growth factor receptors [39] and 
neurotransmitter receptors [40, 41], both of which are essen-
tial for neuronal maintenance and function. CHMP2B
Intron5 
expression can also activate the Toll-like receptor pathway 
[42], which has been implicated in neurodegeneration [43]. 
Further research, including the development of mouse mod-
els, will be required to determine how these different path-
ways contribute to the neuronal cell death caused by 
CHMP2B mutation. 
Autophagy 
  Autophagy is a cellular system that can degrade damaged 
organelles, long-lived proteins and protein aggregates [44]. 
The proteins or organelles to be degraded are encapsulated 
by autophagosomes, which either fuse directly with 
lysosomes, or first with endosomes forming a hybrid organ-
elle termed an amphisome, which then fuses with the 
lysosome [45, 46]. Expression of CHMP2B C-terminal trun-
cation mutants leads to an accumlation of autophagosomes, 
due to their impaired fusion with endosomes and/or 
lysosomes [47, 48]. Rab7 is also required for auto-
phagosome-lysosome fusion [49], suggesting a similar 
mechanism could be responsible for impairing vesicular fu-
sion events in both the autophagy and endosome-lysosome 
pathways. An accumulation of autophagosomes in affected 
neurons has been observed in Alzheimer’s disease [50, 51], 
Parkinson’s disease [52], and prion diseases [53-57], and 
deletion of key autophagy genes leads to neurodegeneration 
in mice [58, 59]. Deciphering the precise mechanism by 
which mutant CHMP2B affects autophagy may therefore 
have broad relevance for understanding neurodegenerative 
disease mechanisms. 
MISSENSE MUTATIONS IN FTD-MND SPECTRUM 
DISORDERS 
  Five missense mutations Fig. (1) in eight individuals 
have been identified in CHMP2B in a range of FTD-MND 
spectrum disorders (Table 1). A recent study screened 433 
MND patients for CHMP2B mutations and identified 3 dis-
tinct CHMP2B missense mutations in four patients. Interest-
ingly, all 4 patients suffered from primary muscular atrophy 
(PMA), a form of motor neuron disease which predomi-
nantly affects the lower motor neurons [60]. 40 of the 433 
MND cohort were PMA variant cases suggesting that 
CHMP2B mutations could account for 10% of such cases. A 
previous study found no CHMP2B mutations in 538 MND 
cases [61], although it is unclear how many PMA cases were 
present in this cohort. Two of the four PMA cases had the 
same mutation, I29V, which has previously been identified 
in one case of FTD-MND [62] one case of FTD [63], but 
also in one control [64]. The final two PMA mutations, 
T104N and Q206H [60], have not been described in any 
other FTD or MND case. A further two missense mutations 
have been described, N143S, in a case of corticobasal degen-
eration [19], and D148Y in a case of semantic dementia [20]. 
  Three of the eight missense mutation cases have a family 
history (Table 1) but unfortunately samples of family mem-
bers were not available to confirm segregation of the muta-
tions. In order to confirm pathogenicity of the missense mu-
tations it will be important to show that they segregate with 
disease in familial cases. Further clarification is also needed 
on the penetrance of the I29V mutation and the pathogenic 
mechanism of the missense mutations. 
  It is also intriguing that the PMA missense cases have 
TDP-43 pathology [60], whereas FTD-3 cases do not [27]. 
This could be explained by the missense mutations having a 
different effect to the gain of function C-terminal truncation 
mutations. Indirect evidence to support this possibility comes 
from an experiment where loss of function of the ESCRT-III 
complex due to knockdown of CHMP3 (also termed VPS24) 
led to the formation of cytoplasmic TDP-43 aggregates in 
cell culture, whereas expression of CHMP2B
Intron5 did not 
[47]. The generation of knockout and missense mouse mod-
els may shed further light on this issue. In summary, furtherFrontotemporal Dementia Caused by CHMP2B Mutations  Current Alzheimer Research, 2011, Vol. 8, No. 3    249 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Multiple alignment of CHMP2B proteins. Wildtype CHMP2B and C-terminal truncations CHMP2B
Intron5, CHMP2B
Delta10 and 
CHMP2B
Q165X were aligned with CHMP2B homologues from other species. The novel C-termini of CHMP2B
Intron5 and CHMP2B
Delta10 are 
highlighted in yellow. CHMP2B missense mutations identified in FTD-MND spectrum disorders are arrowed.  
Table 1.  Cases Identified with CHMP2B Missense Mutations.  
DNA Change  Protein Change  Disease  Family History  Controls Analysed in Study  Reference 
c.85A>G I29V  FTD  Y  190  [63] 
c.85A>G I29V  FTD-MND  Possible  640  [62] 
c.85A>G I29V  PMA  N  500  [60] 
c.85A>G I29V  PMA  N  500  [60] 
c.311C>A  T104N PMA  Y  500  [60] 
c.428A>G N143S  CBD  Y  459  [19] 
c.442G>T D148Y  SD  N  100  [20] 
c.618A>C Q206H  PMA  N  500  [60] 
FTD-MND – Frontotemporal Dementia with Motor Neuron Disease. PMA – Primary Muscular Atrophy. CBD – Corticobasal Degeneration. SD – Semantic Dementia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Representative brain scans in FTD-3 patients. Upper row: structural scans in FTD-3 with MRI for patients A and B, and a CT-scan 
for patient C. Lower row shows cerebral blood flow as measured by with H2
15O -PET scanning for the same 3 patients. 
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work is required to fully assess the role and importance of 
CHMP2B missense mutations in FTD and MND. 
CONCLUSIONS 
  The early clinical picture of FTD caused by CHMP2B 
mutations is similar to other behavioural variant FTD cases 
while the brain imaging and neuropathological findings are 
somewhat distinct. Despite being a rare cause of dementia, 
recent advances in our understanding of the molecular basis 
of  CHMP2B mutations indicate that the mechanisms in-
volved may be broadly relevant to neurodegenerative proc-
esses. 
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ABBREVIATIONS 
CBD =  Corticobasal  degeneration 
CHMP2B  =  Charged multivesicular body protein 2B 
CT =  Computerised  tomography 
ESCRT-III  =  Endosmal sorting complex required for 
transport-III 
FTD-3  =  Frontotemporal dementia linked to chromo-
some three 
FTLD  =  Frontotemporal lobar degeneration 
GRN =  Progranulin 
Vps24  =  Vacuolar protein for sorting 24 
MAPT  =  Microtubule associated protein tau 
MND  =  Motor neuron disease 
MRI  =  Magnetic resonance imaging 
PET =  Positron  emission  tomography 
PMA  =  Primary muscular atrophy 
PNFA  =  Progressive non-fluent aphasia 
SD =  Semantic  dementia 
TDP-43  =  TAR DNA binding protein-43 
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